Hesham Allam, MD

The primary goals of this study are to determine whether treatment of obstructive sleep apnea with positive airway pressure starting shortly after accute ischemic stroke or high risk TIA (1) reduces recurrent stroke, acute coronary syndrome, and all-cause mortality 6 months after the event and (2) improves stroke outcomes at 3 months in patients who experienced ischemic stroke.

18-513:  The purpose of this study is to evaluate the effect of andexanet alfa (andexanet) versus usual care on the rate of effective homostasis.

ANNEXa-1 (18-513): This is a randomized, multicenter clinical trial designed to determine the efficacy and safety of andexanet compared to usual care in patients presenting with acute intracerebral hemorrhage within 6 hours of symptom onset (from the baseline scan) and within 15 hours of taking an oral FXa inhibitor (from randomization). The study will use a prospective, randomized, open-label design, as it is unfeasible to blind the Investigator to the treatment assignment given the many potential therapeutic options available under usual care treatment.

The primary goals of this study are to determine whether (1) treatment of obstructive sleep apnea (OSA) with positive airway pressure after acute ischemic stroke or high risk TIA reduces recurrent stroke, acute coronary syndrome (ACS), and all-cause mortality 6 months after the event, and (2) treatment of OSA shortly after acute ischemic stroke improves stroke outcomes at 3 months.